GH secretagogues: raising a hormone isn't the same as slowing aging

Growth-hormone secretagogues — sermorelin, ipamorelin, and the other GHRH and ghrelin-receptor peptides — are marketed with a simple, seductive syllogism: growth hormone falls with age, these raise growth hormone, therefore they fight aging. The first two clauses are true. The conclusion is where the whole thing quietly falls apart, and understanding why is the entire point of this entry.

The mechanism is real and well characterized. Sermorelin is a GHRH analog and ipamorelin is a selective GH secretagogue acting through the ghrelin receptor; both prompt the pituitary to release more growth hormone, which raises IGF-1 downstream. So yes — take these and a hormone level goes up. But “a hormone level goes up” is a laboratory result, not a health outcome, and the marketing depends on you not noticing the difference.

What the evidence actually shows

Here’s the problem: there is no trial showing GH secretagogues slow aging or improve healthspan in healthy adults. None. And we have a very relevant proxy for what happens when you raise this axis on purpose — the trials of growth hormone itself in healthy older people. A systematic review pooling those studies found that GH produced only small body-composition shifts (a couple of kilograms of fat down, lean mass up) with no proven functional benefit — and meanwhile significantly increased soft-tissue edema, joint pain, carpal tunnel syndrome, and glucose intolerance / new-onset diabetes. The authors concluded GH cannot be recommended as an anti-aging therapy.

That is the most honest available read on the whole category. Secretagogues push the same GH/IGF-1 axis; there is no good reason to expect the risk profile to be gentler, and no outcome data showing benefit that GH itself failed to deliver. This is why the evidence grade is D — not because the peptides do nothing, but because the thing they do has no demonstrated payoff and a documented downside.

The risks worth naming

• Metabolic: raising GH tends to worsen insulin sensitivity and glucose handling — the opposite of what most people over 40 want.
• Musculoskeletal / fluid: edema, arthralgia, and carpal tunnel were consistent adverse effects in the GH trials.
• The IGF-1 question: chronically elevating IGF-1 is a theoretical cancer concern. In ~394,000 UK Biobank participants, higher circulating IGF-1 was associated with increased risk of several cancers. That’s an observational association with the body’s own IGF-1 — not proof that a secretagogue causes cancer — but it’s a biologically plausible reason for caution when the plan is to raise IGF-1 for decades.

The regulatory and real-world context

None of this is FDA-approved for aging. In the US, providing GH-axis therapy for aging or age-related decline is not an approved use and is legally restricted — GH is prescribable only for specific deficiency states. Ipamorelin has no FDA approval at all and circulates as a compounded or “research” product; sermorelin’s history is as a diagnostic/deficiency agent, never an anti-aging one. In practice this is a wellness-clinic and gray-market space, with the sourcing and purity uncertainties that come with it.

The honest bottom line

Raising a hormone is not the same as improving a life, and this is the category where that confusion is most expensively sold. The one population for whom GH-axis evaluation is legitimate is people with genuine, diagnosed growth-hormone deficiency — a real endocrine condition assessed and managed by a specialist. For a healthy adult chasing longevity, the evidence points the other way: no proven benefit, real metabolic and joint downsides, an unresolved IGF-1/cancer question, and no regulatory footing. If you’re drawn to it, the move is an endocrinologist and honest testing — not a clinic membership and a weekly injection.